Peter H Asdahl1,2, Jeanette F Winther2, Trine G Bonnesen1,2, Sofie De Fine Licht2, Thorgerdur Gudmundsdottir2,3, Harald Anderson4, Laura Madanat-Harjuoja5,6, Laufey Tryggvadottir7,8, Milada Cvancarova Småstuen9, Anna Sällfors Holmqvist10, Henrik Hasle1, Jørgen H Olsen2. 1. Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark. 2. Danish Cancer Society Research Center, Copenhagen, Denmark. 3. Children's Hospital Iceland, Landspitali University Hospital, Reykjavik, Iceland. 4. Department of Clinical Sciences, Lund, Cancer Epidemiology, Lund University, Sweden. 5. Finnish Cancer Registry, Helsinki, Finland. 6. Department of Pediatrics, Jorvi Central Hospital, Espoo, Finland. 7. Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 8. Icelandic Cancer Registry, Reykjavik, Iceland. 9. Norwegian Cancer Registry, Oslo, Norway. 10. Department of Clinical Sciences, Pediatric Oncology and Hematology, Skåne University Hospital, Lund University, Lund, Sweden.
Abstract
BACKGROUND: During the last five decades, survival of childhood cancer has increased from 25% to 80%. At the same time, however, it has become evident that survivors experience a broad range of therapy-related late adverse health effects. The aim of the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study is to investigate long-term health consequences of past and current therapies in order to improve follow-up care of survivors and to reduce treatment-related morbidity of future patients. PROCEDURE: Childhood cancer survivors were identified through the five Nordic cancer registries and a comparison cohort was established through random selection of cancer-free individuals from the civil registration systems. A unique personal identification number was used to link between different health registries. Abstraction of treatment information for a subset of survivors allows investigation of the association between the various components of cancer therapy and late occurring comorbidity. RESULTS: The childhood cancer survivor cohort comprises 33,160 1-year survivors and the comparison cohort comprises 212,892 cancer free individuals from the general population. In the childhood cancer survivor cohort, all types of childhood cancer are represented including leukemia (21%), lymphoma (14%), central nervous system tumors (24%), sarcomas (5%), retinoblastoma (3%), and neuroblastoma (4%). Among the survivors, 22% have been followed beyond the age of 40 years. CONCLUSION: The ALiCCS study constitutes a new large resource for research on late effects of childhood cancers that include all types of childhood malignancies and has followed a large proportion of the survivors well into late adulthood.
RCT Entities:
BACKGROUND: During the last five decades, survival of childhood cancer has increased from 25% to 80%. At the same time, however, it has become evident that survivors experience a broad range of therapy-related late adverse health effects. The aim of the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study is to investigate long-term health consequences of past and current therapies in order to improve follow-up care of survivors and to reduce treatment-related morbidity of future patients. PROCEDURE: Childhood cancer survivors were identified through the five Nordic cancer registries and a comparison cohort was established through random selection of cancer-free individuals from the civil registration systems. A unique personal identification number was used to link between different health registries. Abstraction of treatment information for a subset of survivors allows investigation of the association between the various components of cancer therapy and late occurring comorbidity. RESULTS: The childhood cancer survivor cohort comprises 33,160 1-year survivors and the comparison cohort comprises 212,892 cancer free individuals from the general population. In the childhood cancer survivor cohort, all types of childhood cancer are represented including leukemia (21%), lymphoma (14%), central nervous system tumors (24%), sarcomas (5%), retinoblastoma (3%), and neuroblastoma (4%). Among the survivors, 22% have been followed beyond the age of 40 years. CONCLUSION: The ALiCCS study constitutes a new large resource for research on late effects of childhood cancers that include all types of childhood malignancies and has followed a large proportion of the survivors well into late adulthood.
Authors: Gitte Vrelits Sørensen; Jeanette Falck Winther; Sofie de Fine Licht; Klaus Kaa Andersen; Anna Sällfors Holmqvist; Laura Madanat-Harjuoja; Laufey Tryggvadottir; Andrea Bautz; Timothy L Lash; Henrik Hasle Journal: J Natl Cancer Inst Date: 2019-09-01 Impact factor: 13.506
Authors: Sofie de Fine Licht; Kathrine Rugbjerg; Thorgerdur Gudmundsdottir; Trine G Bonnesen; Peter Haubjerg Asdahl; Anna Sällfors Holmqvist; Laura Madanat-Harjuoja; Laufey Tryggvadottir; Finn Wesenberg; Henrik Hasle; Jeanette F Winther; Jørgen H Olsen Journal: PLoS Med Date: 2017-05-09 Impact factor: 11.069
Authors: Desiree Grabow; Melanie Kaiser; Lars Hjorth; Julianne Byrne; Daniela Alessi; Rodrigue S Allodji; Francesca Bagnasco; Edit Bárdi; Andrea Bautz; Chloe J Bright; Florent de Vathaire; Elizabeth A M Feijen; Stanislaw Garwicz; Oskar Hagberg; Riccardo Haupt; Mike M Hawkins; Zsuzsanna Jakab; Leontien C M Kremer; Claudia E Kuehni; Rahel Kuonen; Päivi Maria Lähteenmäki; Raoul C Reulen; Cécile M Ronckers; Carlotta Sacerdote; Giao Vu-Bezin; Finn Wesenberg; Thomas Wiebe; David L Winter; Jeanette Falck Winther; Lorna Zadravec Zaletel; Peter Kaatsch Journal: Eur J Epidemiol Date: 2018-03-02 Impact factor: 8.082
Authors: Kjetil A Van Der Wel; Olof Östergren; Olle Lundberg; Kaarina Korhonen; Pekka Martikainen; Anne-Marie Nybo Andersen; Stine Kjaer Urhoj Journal: Scand J Public Health Date: 2019-07-10 Impact factor: 3.021
Authors: Sanna M M Heikkinen; Laura-Maria Madanat-Harjuoja; Karri J M Seppä; Matti E Rantanen; Elli M Hirvonen; Nea K Malila; Janne M Pitkäniemi Journal: Int J Cancer Date: 2019-06-27 Impact factor: 7.396